Sign In
24 Jun 2015 07:00
24 June 2015
Midatech Pharma PLC
("Midatech" or the "Company")
Director's Share Purchase
Midatech (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, was informed that on 23 June 2015 one of its Directors acquired ordinary shares of 0.005p each ("Ordinary Shares") for his self-invested personal pension fund as follows:
Director / PDMR | Title | Price per share (p) | Number of Ordinary Shares acquired | Resulting direct beneficial interest in the Company | Direct beneficial interest as a % of total issued share capital |
Jim Phillips | Chief Executive Officer | 287 | 2,000 | 33,339 | 0.12% |
- Ends -
For more information, please contact:
Midatech Pharma PLC
Jim Phillips, CEO
Tel: +44 (0)1235 841575
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Corporate Finance
Freddy Crossley / Adam James / Atholl Tweedie / Duncan Monteith
Broking
Tom Salvesen
Tel: +44 (0)20 7886 2500
Consilium Strategic Communications (Financial PR)
Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys
Tel: +44 (0)20 3709 5700
Email: midatech@consilium-comms.com
About Midatech Pharma PLC
Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. These diseases include diabetes, rare cancers including brain (glioblastoma), ovarian, liver and pancreatic cancer and neurological/ophthalmologic conditions. Midatech's strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.
Midatech's core product candidates derive from its two multi-applicable platform technologies that can be used alone or in combination to enable the targeted delivery ('right place') and controlled release ('right time') of existing drugs. These technologies are provided through its wholly-owned subsidiaries, Midatech and Q-Chip (acquired in 2014). Midatech's core platform is a drug conjugate delivery system based on a patented form of gold nanoparticles (GNP) combined with existing drugs for the safe and targeted release of therapeutic payloads at specific organs, cells or sites of disease.
The Group's second platform is a sustained release technology acquired with Q Chip that involves the consistent and precise encapsulation of active drug compounds within polymer microspheres enabling their release into the body in a highly controlled manner over a prolonged period of time.
On 4 June 2015, Midatech announced a proposed acquisition of DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company, based in Raleigh, NC. The acquisition brings a portfolio of marketed oncology products and a salesforce in US to Midatech and is expected to complete in H2 2015.
The Group is headquartered near Oxford, UK, with a nanoparticle manufacturing operation in Bilbao, Spain and an R&D facility in Cardiff, UK. For further company information see: www.midatechgroup.com.
Follow the stocks
